BRIEF-Biogen And Stoke Therapeutics Present Data That Further Support The Disease-Modifying Potential Of Zorevunersen

Reuters12-05

BRIEF-Biogen And Stoke <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Present Data That Further Support The Disease-Modifying Potential Of Zorevunersen

Dec 5 (Reuters) - Biogen Inc BIIB.O:

BIOGEN AND STOKE THERAPEUTICS PRESENT DATA THAT FURTHER SUPPORT THE DISEASE-MODIFYING POTENTIAL OF ZOREVUNERSEN, AN INVESTIGATIONAL MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME, AT THE 2025 AMERICAN EPILEPSY SOCIETY $(AES)$ ANNUAL MEETING

Source text: ID:nGNXFdXG1

Further company coverage: BIIB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589481868?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589481868","market":"fut","top_or_hot":-1,"title":"BRIEF-Biogen And Stoke Therapeutics Present Data That Further Support The Disease-Modifying Potential Of Zorevunersen","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Biogen And Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Present Data That Further Support The Disease-Modifying Potential Of Zorevunersen</title></head><body><p><span>Dec 5 (Reuters)</span><span> - </span>Biogen Inc <span>BIIB.O</span>:</p><ul><li><p>BIOGEN AND STOKE THERAPEUTICS PRESENT DATA THAT FURTHER SUPPORT THE DISEASE-MODIFYING POTENTIAL OF ZOREVUNERSEN, AN INVESTIGATIONAL MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME, AT THE 2025 AMERICAN EPILEPSY SOCIETY <a href=\"https://laohu8.com/S/AES\">$(AES)$</a> ANNUAL MEETING</p></li></ul><p>Source text: <span>ID:nGNXFdXG1</span></p><p>Further company coverage: <span>BIIB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Biogen And Stoke Therapeutics Present Data That Further Support The Disease-Modifying Potential Of Zorevunersen</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Biogen And Stoke Therapeutics Present Data That Further Support The Disease-Modifying Potential Of Zorevunersen\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-05 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Biogen And Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Present Data That Further Support The Disease-Modifying Potential Of Zorevunersen</title></head><body><p><span>Dec 5 (Reuters)</span><span> - </span>Biogen Inc <span>BIIB.O</span>:</p><ul><li><p>BIOGEN AND STOKE THERAPEUTICS PRESENT DATA THAT FURTHER SUPPORT THE DISEASE-MODIFYING POTENTIAL OF ZOREVUNERSEN, AN INVESTIGATIONAL MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME, AT THE 2025 AMERICAN EPILEPSY SOCIETY <a href=\"https://laohu8.com/S/AES\">$(AES)$</a> ANNUAL MEETING</p></li></ul><p>Source text: <span>ID:nGNXFdXG1</span></p><p>Further company coverage: <span>BIIB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B894F039.SGD","symbol_name":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA3XTQYT:1","article_id":"2589481868","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589481868","pubTimestamp":1764943331,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Biogen And Stoke Therapeutics Present Data That Further Support The Disease-Modifying Potential OfZorevunersenDec 5 (Reuters) - Biogen Inc BIIB.O:BIOGEN AND STOKE THERAPEUTICS PRESENT DATA THAT ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4588":"碎股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","STOK":"Stoke Therapeutics, Inc.","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","BIIB":"渤健公司","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD"},"translate_title":"简介-Biogen和Stoke Therapeutics提供的数据进一步支持Zorevunersen的疾病缓解潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STOK":0.9,"BIIB":0.9},"content_text":"BRIEF-Biogen And Stoke Therapeutics Present Data That Further Support The Disease-Modifying Potential Of ZorevunersenDec 5 (Reuters) - Biogen Inc BIIB.O:BIOGEN AND STOKE THERAPEUTICS PRESENT DATA THAT FURTHER SUPPORT THE DISEASE-MODIFYING POTENTIAL OF ZOREVUNERSEN, AN INVESTIGATIONAL MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME, AT THE 2025 AMERICAN EPILEPSY SOCIETY $(AES)$ ANNUAL MEETINGSource text: ID:nGNXFdXG1Further company coverage: BIIB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589481868","isCrawlerRequest":true}